tetano
Editor, Senior Moderator
Arch Pharm (Weinheim). 2019 Oct 28:e1900174. doi: 10.1002/ardp.201900174. [Epub ahead of print] [h=1]Bioassay of ferulic acid derivatives as influenza neuraminidase inhibitors.[/h]
Cui MY[SUP]1[/SUP], Xiao MW[SUP]1[/SUP], Xu LJ[SUP]2[/SUP], Chen Y[SUP]1[/SUP], Liu AL[SUP]2[/SUP], Ye J[SUP]1[/SUP], Hu AX[SUP]1[/SUP].
[h=3]Author information[/h] 1 College of Chemistry and Chemical Engineering, Hunan University, Changsha, China. 2 Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
[h=3]Abstract[/h] Four series of ferulic acid derivatives were designed, synthesized, and evaluated for their neuraminidase (NA) inhibitory activities against influenza virus H1N1 in vitro. The pharmacological results showed that the majority of the target compounds exhibited moderate influenza NA inhibitory activity, which was also better than that of ferulic acid. The two most potent compounds were 1m and 4a with IC[SUB]50[/SUB] values of 12.77 ? 0.47 and 12.96 ? 1.34 μg/ml, respectively. On the basis of the biological results, a preliminary structure-activity relationship (SAR) was derived and discussed. Besides, molecular docking was performed to study the possible interactions of compounds 1p, 2d, 3b, and 4a with the active site of NA. It was found that the 4-OH-3-OMe group and the amide group (CON) of ferulic acid amide derivatives were two key pharmacophores for NA inhibitory activity. It is meaningful to further modify the natural product ferulic acid to improve its influenza NA inhibitory activity.
? 2019 Deutsche Pharmazeutische Gesellschaft.
[h=4]KEYWORDS:[/h] ferulic acid derivatives; molecular docking; neuraminidase inhibitors
PMID: 31657061 DOI: 10.1002/ardp.201900174
Cui MY[SUP]1[/SUP], Xiao MW[SUP]1[/SUP], Xu LJ[SUP]2[/SUP], Chen Y[SUP]1[/SUP], Liu AL[SUP]2[/SUP], Ye J[SUP]1[/SUP], Hu AX[SUP]1[/SUP].
[h=3]Author information[/h] 1 College of Chemistry and Chemical Engineering, Hunan University, Changsha, China. 2 Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
[h=3]Abstract[/h] Four series of ferulic acid derivatives were designed, synthesized, and evaluated for their neuraminidase (NA) inhibitory activities against influenza virus H1N1 in vitro. The pharmacological results showed that the majority of the target compounds exhibited moderate influenza NA inhibitory activity, which was also better than that of ferulic acid. The two most potent compounds were 1m and 4a with IC[SUB]50[/SUB] values of 12.77 ? 0.47 and 12.96 ? 1.34 μg/ml, respectively. On the basis of the biological results, a preliminary structure-activity relationship (SAR) was derived and discussed. Besides, molecular docking was performed to study the possible interactions of compounds 1p, 2d, 3b, and 4a with the active site of NA. It was found that the 4-OH-3-OMe group and the amide group (CON) of ferulic acid amide derivatives were two key pharmacophores for NA inhibitory activity. It is meaningful to further modify the natural product ferulic acid to improve its influenza NA inhibitory activity.
? 2019 Deutsche Pharmazeutische Gesellschaft.
[h=4]KEYWORDS:[/h] ferulic acid derivatives; molecular docking; neuraminidase inhibitors
PMID: 31657061 DOI: 10.1002/ardp.201900174